UNLABELLED: Recent advances in therapeutics are now providing a wide range of options for adults and children living with hemophilia. Although therapeutic choices are also increasing for the youngest individuals with severe disease, challenges remain about early management decisions, as supporting data are currently limited. Parents and healthcare professionals are tasked with helping children achieve an inclusive quality of life and maintain good joint health into adulthood. Primary prophylaxis is the gold standard to optimize outcomes and is recommended to start before 2 years of age. A range of topics need to be discussed with parents to aid their understanding of the decisions they can make and how these will affect the management of their child/children. For those with a family history of hemophilia, prenatal considerations include the possibility of genetic counseling, prenatal investigations, and planning for delivery, together with monitoring of the mother and neonate, as well as diagnosis of the newborn and treatment of any birth-associated bleeding. Subsequent considerations, which are also applicable to families where infant bleeding has resulted in a new diagnosis of sporadic hemophilia, involve explaining bleed recognition and treatment options, practical aspects of initiating/continuing prophylaxis, dealing with bleeds, and ongoing aspects of treatment, including possible inhibitor development. Over time, optimizing treatment efficacy, in which individualizing therapy around activities can play a role, and long-term considerations, including retaining joint health and tolerance maintenance, become increasingly important. The evolving treatment landscape is creating a need for continually updated guidance. Multidisciplinary teams and peers from patient organizations can help provide relevant information. Easily accessible, multidisciplinary comprehensive care remains a foundation to care. Equipping parents early with the knowledge to facilitate truly informed decision-making will help achieve the best possible longer-term health equity and quality of life for the child and family living with hemophilia. PLAIN LANGUAGE SUMMARY: Points to be taken into account to help families make decisions to best care for children born with hemophilia Medical advances are providing a range of treatment options for adults and children with hemophilia. There is, however, relatively limited information about managing newborns with the condition. Doctors and nurses can help parents to understand the choices for infants born with hemophilia. We describe the various points doctors and nurses should ideally discuss with families to enable informed decision-making. We focus on infants who require early treatment to prevent spontaneous or traumatic bleeding (prophylaxis), which is recommended to start before 2 years of age. Families with a history of hemophilia may benefit from discussions before pregnancy, including how an affected child would be treated to protect against bleeds. When mothers are pregnant, doctors can explain investigations that can provide information about their unborn child, plan for the birth, and monitor mother and baby to minimize bleed risks at delivery. Testing will confirm whether the baby is affected by hemophilia. Not all infants with hemophilia will be born to families with a history of the condition. Identification of hemophilia for the first time in a family (which is 'sporadic hemophilia') occurs in previously undiagnosed infants who have bleeds requiring medical advice and possibly hospital treatment. Before any mothers and babies with hemophilia are discharged from hospital, doctors and nurses will explain to parents how to recognize bleeding and available treatment options can be discussed. Over time, ongoing discussions will help parents to make informed treatment decisions:• When and how to start, then continue, prophylaxis.• How to deal with bleeds (reinforcing previous discussions about bleed recognition and treatment) and other ongoing aspects of treatment. ○ For instance, children may develop neutralizing antibodies (inhibitors) to treatment they are receiving, requiring a change to the planned approach.• Ensuring treatment remains effective as their child grows, considering the varied needs and activities of their child.

Clinical and Molecular Hemostasis Department of Pediatrics University Hospital Frankfurt Goethe University Frankfurt Germany

Department of Pediatric Hematology University Hospital Brno and Masaryk University Brno Czech Republic

Department of Translational Medicine Lund University and Department of Hematology Oncology and Radiation Physics Skåne University Hospital Jan Waldenströms gata 14 SE 205 02 Malmö Sweden

Hematology Department Hospital Universitario La Paz Autónoma University Madrid Spain

Hemostasis and Thrombosis Unit Division of Hematology Cliniques Universitaires Saint Luc Université catholique de Louvain Brussels Belgium

The Royal London Hospital Haemophilia Centre Barts and the London School of Medicine QMUL London UK

Zobrazit více v PubMed

Nijdam A, Altisent C, Carcao MD, et al. Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades. Haematologica 2015; 100: e84–e86. PubMed PMC

Berntorp E, Astermark J, Björkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia 2003; 9(Suppl. 1): 1–4. PubMed

Blanchette VS, Key NS, Ljung LR, et al. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2014; 12: 1935–1939. PubMed

Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia, 3rd edition. Haemophilia 2020; 26(Suppl. 6): 1–158. PubMed

Astermark J, Petrini P, Tengborn L, et al. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109–1113. PubMed

Van den Berg HM, Dunn A, Fischer K, et al. Prevention and treatment of musculoskeletal disease in the haemophilia population: role of prophylaxis and synovectomy. Haemophilia 2006; 12(Suppl. 3): 159–168. PubMed

Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–544. PubMed

Ghosh K, Ghosh K.Management of haemophilia in developing countries: challenges and options. Indian J Hematol Blood Transfus 2016; 32: 347–355. PubMed PMC

Alabek M, Mohan R, Raia M. Genetic counselling for Hemophilia. Treatment of hemophilia monograph no. 25, https://www1.wfh.org/publications/files/pdf-1160.pdf (2015, accessed November 2022).

Streif W, Knöfler R.Perinatal management of haemophilia. Hamostaseologie 2020; 40: 226–232. PubMed

Moorehead PC, Chan AKC, Lemyre B, et al. A practical guide to the management of the fetus and newborn with hemophilia. Clin Appl Thromb Hemost 2018; 24(Suppl.): 29S–41S. PubMed PMC

Hermans C, Kulkarni R.Women with bleeding disorders. Haemophilia 2018; 24(Suppl. 6): 29–36. PubMed

UKHCDO. Clinical genetics services for haemophilia, http://www.ukhcdo.org/wp-content/uploads/2015/12/Guidelines_on_genetics_services_for_haemophilia_v5-3_1_final.pdf (2018, accessed November 2022).

Shoukat HMH, Ghous G, Tarar ZI, et al. Skewed inactivation of X chromosome: a cause of hemophilia manifestation in carrier females. Cureus 2020; 12: e11216. PubMed PMC

Chi C, Lee CA, Shiltagh N, et al. Pregnancy in carriers of haemophilia. Haemophilia 2008; 14: 56–64. PubMed

James PD, Mahlangu J, Bidlingmaier C, et al. Evaluation of the utility of the ISTH-BAT in haemophilia carriers: a multinational study. Haemophilia 2016; 22: 912–918. PubMed

James AH, Konkle BA, Kouides P, et al. Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis. Haemophilia 2015; 21: 81–87. PubMed

Pavord S, Rayment R, Madan B, et al. Management of inherited bleeding disorders in pregnancy: green-top guideline no. BJOG 2017; 124: e193–e263. PubMed

Dunkley S, Curtin JA, Marren AJ, et al. Updated Australian consensus statement on management of inherited bleeding disorders in pregnancy. Med J Aust 2019; 210: 326–332. PubMed PMC

Kulkarni R, Lusher JM.Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature. J Pediatr Hematol Oncol 1999; 21: 289–295. PubMed

Kulkarni R, Soucie JM, Lusher J, et al. Sites of initial bleeding episodes, mode of delivery and age of diagnosis in babies with haemophilia diagnosed before the age of 2 years: a report from The Centers for Disease Control and Prevention’s (CDC) Universal Data Collection (UDC) project. Haemophilia 2009; 15: 1281–1290. PubMed

Zwagemaker AF, Gouw SC, Jansen JJ, et al. Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis. Blood 2021; 138: 2853–2873. PubMed

Andersson NG, Chalmers EA, Kenet G, et al. Mode of delivery in hemophilia: vaginal delivery and Cesarean section carry similar risks for intracranial hemorrhages and other major bleeds. Haematologica 2019; 104: 2100–2106. PubMed PMC

Zanon E, Pasca S.Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years. Blood Transfus 2019; 17: 378–384. PubMed PMC

Chalmers E, Williams M, Brennand J, et al. Guideline on the management of haemophilia in the fetus and neonate. Br J Haematol 2011; 154: 208–215. PubMed

van Galen K, Lavin M, Skouw-Rasmussen N, et al. European principles of care for women and girls with inherited bleeding disorders. Haemophilia 2021; 27: 837–847. PubMed

van Galen KPM, d’Oiron R, James P, et al. A new hemophilia carrier nomenclature to define hemophilia in women and girls: communication from the SSC of the ISTH. J Thromb Haemost 2021; 19: 1883–1887. PubMed PMC

d’Oiron R, O’Brien S, James AH.Women and girls with haemophilia: lessons learned. Haemophilia 2021; 27(Suppl. 3): 75–81. PubMed

Kenet G, Chan AK, Soucie JM, et al. Bleeding disorders in neonates. Haemophilia 2010; 16(Suppl. 5): 168–175. PubMed

Davenport P, Sola-Visner M.Hemostatic challenges in neonates. Front Pediatr 2021; 9: 627715. PubMed PMC

Chalmers EA, Alamelu J, Collins PW, et al. Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003–2015: a national cohort study. Haemophilia 2018; 24: 641–647. PubMed

Kurnik K, Bidlingmaier C, Olivieri M.How do I counsel parents of a newly diagnosed boy with haemophilia A. Hamostaseologie 2020; 40: 88–96. PubMed

Kulkarni R, Presley RJ, Lusher JM, et al. Complications of haemophilia in babies (first two years of life): a report from the Centers for Disease Control and Prevention Universal Data Collection system. Haemophilia 2017; 23: 207–214. PubMed PMC

Dodd Wilson I. Chapter 85. Hematemesis, melena and hematochezia. In: Walker HK, Hall WD, Hurst JW. (eds) Clinical methods: the history, physical, and laboratory examinations. Boston, MA: Butterworths, 1990, pp. 439–442. PubMed

Peyvandi F, Berger K, Seitz R, et al. Kreuth V initiative: European consensus proposals for treatment of hemophilia using standard products, extended half-life coagulation factor concentrates and non-replacement therapies. Haematologica 2020; 105: 2038–2043. PubMed PMC

European Medicines Agency. Elocta (rFVIIIFc) summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/elocta-epar-product-information_en.pdf (2021, accessed November 2022).

Bioverativ Therapeutics Inc. Eloctate® prescribing information, https://www.fda.gov/media/88746/download (2020, accessed November 2022).

European Medicines Agency. Alprolix® summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/alprolix-epar-product-information_en.pdf (2021, accessed November 2022).

Bioverativ Therapeutics Inc. Alprolix® prescribing information, http://products.sanofi.us/Alprolix/alprolix.pdf (2020, accessed November 2022).

European Medicines Agency. Idelvion® summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/idelvion-epar-product-information_en.pdf (2021, accessed November 2022).

CSL Behring. Idelvion prescribing information, https://www.idelvion.com/prescribing-information (2021, accessed November 2022).

Baxalta. Adynovate prescribing information, https://www.fda.gov/media/94470/download (2021, accessed November 2022).

Novo Nordisk. Esperoct prescribing information, https://www.fda.gov/media/120351/download (2019, accessed November 2022).

Novo Nordisk. Rebinyn prescribing information, https://www.novo-pi.com/rebinyn.pdf (2022, accessed November 2022).

European Medicines Agency. Adynovi summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/adynovi-epar-product-information_en.pdf (2022, accessed November 2022).

European Medicines Agency. Esperoct summary of product characteristics, https://www.ema.europa.eu/en/medicines/human/EPAR/esperoct (2020, accessed November 2022).

European Medicines Agency. Jivi summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/jivi-epar-product-information_en.pdf (2021, accessed November 2022).

European Medicines Agency. Refixia summary of product characteristics, https://www.ema.europa.eu/en/documents/product-information/refixia-epar-product-information_en.pdf (2022, accessed November 2022).

Bayer Healthcare. Jivi prescribing information, https://labeling.bayerhealthcare.com/html/products/pi/Jivi_PI.pdf (2018, accessed November 2022).

WFH. Online registry of clotting factor concentrates, https://wfh.org/article/wfh-online-registry-of-clotting-factor-concentrates/#:~:text=The%20Online%20CFC%20Registry%20provides,and%20facilitates%20comparisons%20between%20them (2021, accessed November 2022).

Farrugia A.Guide for the assessment of clotting factor concentrates. 3rd ed.Montreal, QC, Canada: World Federation of Hemophilia, https://www1.wfh.org/publication/files/pdf-1271.pdf (2017, accessed November 2022).

Bertamino M, Riccardi F, Banov L, et al. Hemophilia care in the pediatric age. J Clin Med 2017; 6: 54. PubMed PMC

Nijdam A, Kurnik K, Liesner R, et al. How to achieve full prophylaxis in young boys with severe haemophilia A: different regimens and their effect on early bleeding and venous access. Haemophilia 2015; 21: 444–450. PubMed

Mahlangu J, Young G, Hermans C, et al. Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia 2018; 24: 348–358. PubMed

Graf L.Extended half-life factor VIII and factor IX preparations. Transfus Med Hemother 2018; 45: 86–91. PubMed PMC

Rodriguez-Merchan EC, Valentino LA.Emicizumab: review of the literature and critical appraisal. Haemophilia 2019; 25: 11–20. PubMed

Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377: 809–818. PubMed

European Medicines Agency. Hemlibra: EPAR-product information, https://www.ema.europa.eu/en/medicines/human/EPAR/hemlibra#product-information-section (2022, accessed November 2022).

Genetech Inc. Hemlibra® prescribing information, https://www.gene.com/download/pdf/hemlibra_prescribing.pdf (2022, accessed November 2022).

Cafuir L, Kruse-Jarres R, Mancuso ME, et al. Emicizumab for hemophilia A without inhibitors. Expert Rev Hematol 2019; 12: 515–524. PubMed

ClinicalTrialsgov. Study identifier NCT04431726. A study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneous emicizumab in participants from birth to 12 months of age with hemophilia A withoutiInhibitors (HAVEN 7), https://clinicaltrials.gov/ct2/show/NCT04431726 (accessed November 2022).

Batty P, Austin SK, Khair K, et al. Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A. Br J Haematol 2017; 176: 796–804. PubMed

Abdi A, Kloosterman FR, Eckhardt CL, et al. The factor VIII treatment history of non-severe hemophilia A. J Thromb Haemost 2020; 18: 3203–3210. PubMed PMC

Jenkins PV, Bowyer A, Burgess C, et al. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors’ Organisation guideline. Haemophilia 2020; 26: 151–155. PubMed

Samuelson Bannow B, Recht M, Négrier C, et al. Factor VIII: long-established role in haemophilia A and emerging evidence beyond haemostasis. Blood Rev 2019; 35: 43–50. PubMed

Konkle BA, Shapiro AD, Quon DV, et al. BIVV001 fusion protein as factor VIII replacement therapy for hemophilia A. N Engl J Med 2020; 383: 1018–1027. PubMed

Seth Chhabra E, Liu T, Kulman J, et al. BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice. Blood 2020; 135: 1484–1496. PubMed PMC

ClinicalTrialsgov. Study identifier NCT04759131. Safety, efficacy and PK of BIVV001 in pediatric patients with hemophilia A (XTEND-Kids), https://www.clinicaltrials.gov/ct2/show/NCT04759131 (accessed November 2022).

ClinicalTrialsgov. Study identifier NCT05053139. A research study investigating Mim8 in adults and adolescents with haemophilia A with or without inhibitors, https://clinicaltrials.gov/ct2/show/NCT05053139 (accessed November 2022).

Wood JP, Ellery PER, Maroney SA, et al. Biology of tissue factor pathway inhibitor. Blood 2014; 123: 2934–2943. PubMed PMC

Ott I, Miyagi Y, Miyazaki K, et al. Reversible regulation of tissue factor-induced coagulation by glycosyl phosphatidylinositol-anchored tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2000; 20: 874–882. PubMed

ClinicalTrials.gov. Study identifier NCT04083781. Research study to look at how well the drug concizumab works in your body if you have haemophilia with inhibitors (explorer7), https://www.clinicaltrials.gov/ct2/show/NCT04083781 (accessed November 2022).

ClinicalTrials.gov. Study identifier NCT04082429. Research study to look at how well the drug concizumab works in your body if you have haemophilia without inhibitors (explorer8), https://www.clinicaltrials.gov/ct2/show/NCT04082429 (accessed November 2022).

ClinicalTrials.gov. Study identifier NCT03938792. Study of the efficacy and safety PF-06741086 in adult and teenage participants with severe hemophilia A or moderately severe to severe hemophilia B, https://www.clinicaltrials.gov/ct2/show/NCT03938792 (accessed November 2022).

ClinicalTrials.gov. Study identifier NCT05145127. Open-label extension study of marstacimab in hemophilia participants with or without inhibitors, https://www.clinicaltrials.gov/ct2/show/NCT05145127 (accessed November 2022).

ClinicalTrials.gov. Study identifier NCT03549871. A study of fitusiran in severe hemophilia A and B patients previously receiving factor or bypassing agent prophylaxis (ATLAS-PPX), https://www.clinicaltrials.gov/ct2/show/NCT03549871 (accessed November 2022).

ClinicalTrials.gov. Study identifier NCT02554773. An open-label extension study of an investigational drug, fitusiran, in patients with moderate or severe hemophilia A or B, https://www.clinicaltrials.gov/ct2/show/NCT02554773 (accessed November 2022).

Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017; 377: 819–828. PubMed

Polderdijk SGI, Baglin TP, Huntington JA.Targeting activated protein C to treat hemophilia. Curr Opin Hematol 2017; 24: 446–452. PubMed PMC

Zhao XY, Wilmen A, Wang D, et al. Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia. Nat Commun 2020; 11: 2992. PubMed PMC

Butterfield JSS, Hege KM, Herzog RW, et al. A molecular revolution in the treatment of hemophilia. Mol Ther 2020; 28: 997–1015. PubMed PMC

Mancuso ME, Mahlangu JN, Pipe SW.The changing treatment landscape in haemophilia: from standard half-life clotting factor concentrates to gene editing. Lancet 2021; 397: 630–640. PubMed

Pasi KJ, Rangarajan S, Mitchell N, et al. Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A. N Engl J Med 2020; 382: 29–40. PubMed

Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med 2017; 377: 2519–2530. PubMed

Pasi KJ, Laffan M, Rangarajan S, et al. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A. Haemophilia 2021; 27: 947–956. PubMed PMC

Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371: 1994–2004. PubMed PMC

European Medicines Agency. Roctavian. Valoctocogene roxaparvovec, https://www.ema.europa.eu/en/medicines/human/EPAR/roctavian-0 (2022, November2022).

Food Drug Administration. FDA approves first gene therapy to treat adults with hemophilia B, https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treat-adults-hemophilia-b (2022, accessed November 2022).

Sidonio RF, Jr, Pipe SW, Callaghan MU, et al. Discussing investigational AAV gene therapy with hemophilia patients: a guide. Blood Rev 2020; 47: 100759. PubMed

Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT study). J Thromb Haemost 2011; 9: 700–710. PubMed

Collins PW, Obaji SG, Roberts H, et al. Clinical phenotype of severe and moderate haemophilia: who should receive prophylaxis and what is the target trough level? Haemophilia 2021; 27: 192–198. PubMed

PedNet Haemophilia Registry. Protocol of the PedNet haemophilia registry, https://pednet.eu/wp-content/uploads/2020/06/Protocol-of-the-PedNet-Haemophilia-Registry-version-6_05052020.pdf (2020, accessed November 2022).

Königs C, Ozelo MC, Dunn A, et al. First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results. Blood 2022; 139: 3699–3707. PubMed PMC

Chan AK, Alamelu J, Barnes C, et al. Nonacog beta pegol (N9-GP) in hemophilia B: first report on safety and efficacy in previously untreated and minimally treated patients. Res Pract Thromb Haemost 2020; 4: 1101–1113. PubMed PMC

Kenet G, Nolan B, Oldenburg J, et al. Emicizumab treatment in pediatric haemophilia A patients: >1 year safety based on real-world data from the PedNet cohorts [abstract]. Res Pract Thromb Haemost 2021, https://abstracts.isth.org/abstract/emicizumab-treatment-in-pediatric-haemophilia-a-patients-1-year-safety-based-on-real-world-data-from-the-pednet-cohorts/

van den Berg HM, Fischer K, Carcao M, et al. Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood 2019; 134: 317–320. PubMed

Male C, Andersson NG, Rafowicz A, et al. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica 2021; 106: 123–129. PubMed PMC

Hermans C, Giangrande PLF, O’Mahony B, et al. European principles of inhibitor management in patients with haemophilia: implications of new treatment options. Orphanet J Rare Dis 2020; 15: 219. PubMed PMC

DiMichele DM, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13(Suppl. 1): 1–22. PubMed

Valentino LA, Kempton CL, Kruse-Jarres R, et al. US guidelines for immune tolerance induction in patients with haemophilia A and inhibitors. Haemophilia 2015; 21: 559–567. PubMed

Batsuli G, Zimowski KL, Tickle K, et al. Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis. Haemophilia 2019; 25: 789–796. PubMed

Carcao M, Shapiro A, Hwang N, et al. Real-world data of immune tolerance induction using recombinant factor VIII Fc fusion protein in patients with severe haemophilia A with inhibitors at high risk for immune tolerance induction failure: a follow-up retrospective analysis. Haemophilia 2021; 27: 19–25. PubMed PMC

Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia 2019; 25: 676–684. PubMed PMC

Hart DP, Alamelu J, Bhatnagar N, et al. Immune tolerance induction in severe haemophilia A: a UKHCDO inhibitor and paediatric working party consensus update. Haemophilia 2021; 27: 932–937. PubMed

ClinicalTrials.gov. Study identifier NCT04030052. Emicizumab PUPs and Nuwiq ITI study, https://clinicaltrials.gov/ct2/show/NCT04030052 (accessed November 2022).

Paz-Priel I, Chang T, Asikanius E, et al. Immunogenicity of emicizumab in people with hemophilia A (PwHA): results from the HAVEN 1–4 studies. Blood 2018; 132: 633.

Jiménez-Yuste V, Peyvandi F, Klamroth R, et al. Final analysis of the STASEY Trial: a single-arm, multicenter, open-label, phase III clinical trial evaluating the safety and tolerability of emicizumab prophylaxis in persons with hemophilia A (PwHA) with factor (F)VIII inhibitors. Res Pract Thromb Haemost 2021; 5: PB0521.

Harkins Druzgal C, Kizilocak H, Brown J, et al. Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: new case with detailed laboratory evaluation. J Thromb Haemost 2020; 18: 2205–2208. PubMed

ClinicalTrials.gov. Study identifier NCT04204408. A research study investigating Mim8 in people with haemophilia A (FRONTIER1), https://clinicaltrials.gov/ct2/show/NCT04204408 (accessed November 2022).

Shapiro AD, Angchaisuksiri P, Astermark J, et al. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Adv 2022; 6: 3422–3432. PubMed PMC

Katragadda S, Neelakantan S, Diao L, et al. Population pharmacokinetic analysis of recombinant factor VIII Fc fusion protein in subjects with severe hemophilia A: expanded to include pediatric subjects. J Clin Pharmacol 2021; 61: 889–900. PubMed

Fischer K, Ljung R.Primary prophylaxis in haemophilia care: guideline update 2016. Blood Cells Mol Dis 2017; 67: 81–85. PubMed

Iorio A, Iserman E, Blanchette V, et al. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia 2017; 23: e170–e179. PubMed

Valentino LA, Pipe SW, Collins PW, et al. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia 2016; 22: 514–520. PubMed

Ragni MV, Croteau SE, Morfini M, et al. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16: 1437–1441. PubMed

Martin AP, Burke T, Asghar S, et al. Understanding minimum and ideal factor levels for participation in physical activities by people with haemophilia: an expert elicitation exercise. Haemophilia 2020; 26: 711–717. PubMed

Broderick C.Evaluation and management of bleeding risks with athletic activities in children with hemophilia. Clin Adv Hematol Oncol 2013; 11: 46–47. PubMed

Broderick CR, Herbert RD, Latimer J, et al. Association between physical activity and risk of bleeding in children with hemophilia. JAMA 2012; 308: 1452–1459. PubMed

van Os SB, Troop NA, Sullivan KR, et al. Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a quantitative study with patients. PLoS ONE 2017; 12: e0169880. PubMed PMC

Tagliaferri A, Matichecchia A, Rivolta GF, et al. Optimising prophylaxis outcomes and costs in haemophilia patients switching to recombinant FVIII-Fc: a single-centre real-world experience. Blood Transfus 2020; 18: 374–385. PubMed PMC

Santagostino E, Auerswald G, Benson G, et al. Switching treatments in haemophilia: is there a risk of inhibitor development? Eur J Haematol 2015; 94: 284–289. PubMed PMC

Oldenburg J.Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015; 125: 2038–2044. PubMed

Stephensen D, Bladen M, McLaughlin P.Recent advances in musculoskeletal physiotherapy for haemophilia. Ther Adv Hematol 2018; 9: 227–237. PubMed PMC

Young G.From boy to man: recommendations for the transition process in haemophilia. Haemophilia 2012; 18(Suppl. 5): 27–32. PubMed

Mannucci PM.Hemophilia therapy: the future has begun. Haematologica 2020; 105: 545–553. PubMed PMC

Skinner MW, Nugent D, Wilton P, et al. Achieving the unimaginable: health equity in haemophilia. Haemophilia 2020; 26: 17–24. PubMed PMC

Valentino LA, Blanchette V, Negrier C, et al. Personalised haemophilia management with shared decision making. J Haem Pract 2021; 8: 69–79.

World Federation of Hemophilia. Education and eLearning, https://wfh.org/education-and-elearning/ (2022, accessed November 2022).

European Haemophilia Consortium. About bleeding disorders, https://www.ehc.eu/bleeding-disorders/about-bleeding-disorders/ (2019, accessed November 2022).

National Hemophilia Foundation. Bleeding disorders A–Z, https://www.hemophilia.org/bleeding-disorders-a-z (2022, accessed November 2022).

Thornburg CD, Duncan NA.Treatment adherence in hemophilia. Patient Prefer Adherence 2017; 11: 1677–1686. PubMed PMC

Hart DP, Kessler CM, Aledort L.Re-personalization and stratification of hemophilia care in an evolving treatment landscape. Hematology 2019; 24: 737–741. PubMed

Young G.Management of children with hemophilia A: how emicizumab has changed the landscape. J Thromb Haemost 2021; 19: 1629–1637. PubMed

Thornburg CD.How I approach: previously untreated patients with severe congenital hemophilia A. Pediatr Blood Cancer 2018; 65: e27466. PubMed